Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Tax Provisions (2016 - 2020)

Summit Therapeutics filings provide 7 years of Tax Provisions readings, the most recent being -$21000.0 for Q4 2020.

  • Quarterly Tax Provisions changed N/A to -$21000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$21000.0 through Sep 2021, down 102.97% year-over-year, with the annual reading at -$213000.0 for FY2020, 691.67% down from the prior year.
  • Tax Provisions hit -$21000.0 in Q4 2020 for Summit Therapeutics, up from -$56000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.0 million in Q4 2017 and bottomed at -$654347.7 in Q3 2018.
  • Average Tax Provisions over 5 years is $851261.8, with a median of $1.1 million recorded in 2016.
  • The largest annual shift saw Tax Provisions soared 459.29% in 2019 before it crashed 150.45% in 2020.
  • Summit Therapeutics' Tax Provisions stood at $1.2 million in 2016, then tumbled by 100.0% to -$38.52 in 2017, then skyrocketed by 4229516.59% to $1.6 million in 2018, then plummeted by 44.76% to $899800.4 in 2019, then tumbled by 102.33% to -$21000.0 in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Tax Provisions are -$21000.0 (Q4 2020), -$56000.0 (Q3 2020), and -$191000.0 (Q2 2020).